Inogen (NASDAQ:INGN) Share Price Crosses Below Two Hundred Day Moving Average - Should You Sell?

Key Points

• Inogen shares fell below their 200-day moving average, trading as low as $5.54 before closing at $5.98, below the $6.23 long-term average.
• Analyst sentiment is mixed: Weiss Ratings reaffirmed a “sell (D-)” rating, while MarketBeat’s overall consensus remains “Moderate Buy,” split between one Strong Buy and one Sell rating.
• Inogen slightly exceeded quarterly EPS expectations, reporting a loss of $0.14 per share versus the forecasted $0.15 loss, but revenue of $95.08 million was marginally below estimates and the company remains unprofitable.

Inogen, Inc (NASDAQ:INGN - Get Free Report) crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $6.23 and traded as low as $5.54. Inogen shares last traded at $5.98, with a volume of 1,104,957 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inogen in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Inogen presently has an average rating of "Moderate Buy".

Inogen Price Performance

The stock has a fifty day moving average of $5.67 and a 200 day moving average of $6.23. The firm has a market capitalization of $158.71 million, a P/E ratio of -6.64 and a beta of 1.49.

Inogen (NASDAQ:INGN - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical technology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. The firm had revenue of $95.08 million during the quarter, compared to the consensus estimate of $95.23 million. Inogen had a negative return on equity of 13.17% and a negative net margin of 6.94%.

Institutional Trading of Inogen

A number of large investors have recently added to or reduced their stakes in INGN. BlackRock Inc. purchased a new stake in Inogen in the second quarter worth $11,281,000. Armistice Capital LLC raised its stake in shares of Inogen by 46.3% in the fourth quarter. Armistice Capital LLC now owns 1,264,000 shares of the medical technology company's stock valued at $8,494,000 after buying an additional 400,000 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in shares of Inogen by 203.9% in the first quarter. Arrowstreet Capital Limited Partnership now owns 586,159 shares of the medical technology company's stock valued at $3,622,000 after buying an additional 393,310 shares during the period. Readystate Asset Management LP purchased a new position in shares of Inogen during the 2nd quarter valued at $1,718,000. Finally, Monaco Asset Management SAM purchased a new position in shares of Inogen during the 2nd quarter valued at $1,037,000. Hedge funds and other institutional investors own 89.94% of the company's stock.

Inogen Company Profile

Inogen, Inc is a medical technology company that develops, manufactures and distributes oxygen therapy products for people with chronic respiratory conditions. Its offerings are designed to provide supplemental oxygen outside traditional clinical settings, including at home and while traveling.

The company is best known for its Inogen One family of portable oxygen concentrators, which extract oxygen from ambient air and deliver it to patients without requiring refillable oxygen tanks. Inogen also offers stationary oxygen concentrators, accessories and related services, including equipment support and rental programs.

Founded in 2001 and headquartered in Goleta, California, Inogen serves customers through direct-to-consumer sales, health care providers and distributors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.